Selective Renal Cell Differentiation via Defined Culture Medium

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

There is no established method for selectively inducing differentiation of renal collecting duct cells and renal pelvic epithelial cells from human pluripotent stem cells.

Innovation Solution

A method involving the use of a medium comprising TGFβ inhibitors, Wnt inhibitors, phosphodiesterase inhibitors, and retinoic acid receptor agonists, along with the presence of ETS family proteins, to culture ureteric bud cells or their derivatives, enabling the production of renal collecting duct principal cells, intercalated cells, and pelvic epithelial cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional culture methods are used for ureteric bud cells, then general renal tissue differentiation occurs, but selective induction of renal collecting duct cells and pelvic epithelial cells cannot be achieved

Engineering Contradiction:
Improveselective differentiation capabilityVSAvoidculture method complexity
Core Design Contradiction:
Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The patent applies parameter changes by systematically modifying culture medium composition to achieve selective differentiation. Specifically, it uses a defined medium containing TGFβ inhibitor (SB431542), Wnt inhibitor (IWP-2), phosphodiesterase inhibitor (IBMX), and retinoic acid receptor agonist (TTNPB) at optimized concentrations. This chemical parameter modification enables selective induction of renal collecting duct cells and pelvic epithelial cells from ureteric bud cells, resolving the contradiction between selective differentiation capability and culture method complexity.

Inventive Principle:
Principle #35Parameter changes

2Manufacturing precision

If renal collecting duct cells are produced using existing methods, then some renal tissue components are obtained, but high purity cell populations cannot be achieved

Engineering Contradiction:
Improvecell population purityVSAvoidcell production efficiency
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The patent applies preliminary action by first inducing renal collecting duct progenitor cells with specific transcription factors (ELF5, HNF1B, PAX2) before final differentiation. This staged approach, where progenitor cells are prepared in advance with appropriate transcription factor expression, enables subsequent efficient differentiation into high-purity renal collecting duct cells and pelvic epithelial cells, resolving the contradiction between cell population purity and production efficiency.

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentEP4530344A1Production method for renal collecting duct cells and pelvic epithelial cells
Publication Date: 2025.04.02 KYOTO UNIV
  • EP4530344A1 patent drawingFigure 1~4
  • EP4530344A1 patent drawingFigure 5
  • EP4530344A1 patent drawingFigure 6

AI summary

Provided is a method for producing renal collecting duct principal cells, including culturing ureteric bud cells or cells that have been differentiated from ureteric bud cells in a medium comprising a TGFβ inhibitor, a Wnt inhibitor, and a phosphodiesterase inhibitor. Also, provided is a method for producing a renal collecting duct principal cell-containing organoid, including culturing a ureteric bud organoid or an organoid that has been differentiated from a ureteric bud organoid in a medium comprising a TGFβ inhibitor, a Wnt inhibitor, and a phosphodiesterase inhibitor.